Compare FAT & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAT | MIST |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 163.2M |
| IPO Year | 2017 | N/A |
| Metric | FAT | MIST |
|---|---|---|
| Price | $0.43 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $10.00 | $8.50 |
| AVG Volume (30 Days) | 717.8K | ★ 9.3M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $574,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.63 |
| 52 Week High | $6.17 | $3.06 |
| Indicator | FAT | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 23.84 | 40.81 |
| Support Level | $0.42 | $1.61 |
| Resistance Level | $0.50 | $3.06 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 7.10 | 36.21 |
FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires, and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).